SSB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient entry. The stock is in a strong uptrend, but it’s extended (RSI ~73) and sitting close to near-term resistance (R1 ~104), while options positioning is meaningfully defensive (put/call ratios elevated). With no Intellectia buy signals today and the setup skewing toward a near-term pullback rather than immediate upside, the better call is to hold off at current levels.
Trend is bullish but stretched. Moving averages are stacked bullishly (SMA_5 > SMA_20 > SMA_200), confirming an ongoing uptrend. MACD histogram is positive (0.27) but contracting, signaling upside momentum is still positive yet cooling. RSI_6 at ~73.5 indicates the stock is getting overbought/extended, which often precedes consolidation or a dip. Key levels: pivot ~100.75 (first support zone), resistance R1 ~104.06 then R2 ~106.10; supports S1 ~97.44 and S2 ~95.40. Given price ~102.33 post-market, risk/reward for an immediate chase is mediocre (closer to resistance than strong support).
Intellectia Proprietary Trading Signals
Q4 2025 narrative is strong: reported 30%+ EPS growth, 11% dividend increase, and successful integration of Independent Financial. Operational momentum appears solid with ~8% annualized loan and deposit growth in Q4 and management highlighting strong capital ratios and efficiency. Macro/sector tailwinds cited by analysts include curve steepening and resumed buybacks for regional banks.
with momentum cooling (MACD contracting), increasing odds of consolidation/pullback. Options positioning is notably defensive (high put/call ratios). Pattern-based forward odds provided also lean slightly negative over the next month (-3.3% expectation), which aligns with a likely digestion phase after strong results and target upgrades.
Latest provided quarter: 2025/Q2. Growth was strong: Revenue $647.7M (+59.53% YoY), Net Income $215.2M (+62.59% YoY), EPS $2.11 (+21.97% YoY). Overall, this points to strong profitability expansion and solid operating leverage in that period (though more recent Q4 commentary in news also supports continued momentum).
Wall Street trend is clearly improving: multiple firms raised price targets after Q4 results while reiterating bullish ratings (Buy/Overweight/Strong Buy). Recent targets cluster around $119–$126 (DA Davidson $119, Stephens $120, TD Cowen $120, Barclays $126, Citi $120, Raymond James up to $120), implying meaningful upside versus ~$102. Pros cited: above-peer loan growth, stable NIM outlook, fee income traction, active capital return, strong markets footprint, and relatively clean credit. Cons/risk points (implied rather than directly stated): premium valuation justification depends on sustaining above-peer growth; near-term hiring/tech investment could pressure expenses; and after a strong run, timing risk is higher. Influential/ownership flows: Hedge funds neutral (no major trend last quarter), insiders neutral (no major trend last month). Congress trading: no recent data available.
